Potential of biological macromolecules as innovative approach for diabetes management: A review
DOI:
https://doi.org/10.56511/JIPBS.2025.12104Abstract
Diabetes mellitus, a complex and widespread metabolic disorder, presents a significant challenge to global health. While insulin therapy remains a cornerstone of treatment, its limitations, including therapeutic resistance and the development of associated complications, necessitate the exploration of innovative therapeutic strategies. This review delves into the promising realm of biological macromolecules, highlighting their potential to revolutionize diabetes management. We examine the diverse therapeutic applications of enzymes, growth factors, antibodies, polysaccharides, nucleic acids, and stem cells, elucidating their multifaceted roles in addressing the complex pathophysiology of diabetes. These macromolecules exert their therapeutic effects through intricate mechanisms, including precise modulation of glucose homeostasis, robust protection of insulin-producing beta cells, and effective attenuation of oxidative stress, a key driver of diabetic complications. A deep understanding of the metabolic pathways influenced by these molecules is crucial for optimizing their therapeutic efficacy and minimizing potential side effects. Recent advancements in protein engineering, targeted drug delivery systems, and regenerative medicine have paved the way for the development of highly specific, potent, and long-lasting biological macromolecular therapeutics. This review underscores the immense potential of biological macromolecules to transform diabetes care, emphasizing the critical need for continued research and clinical trials to translate these promising findings into clinically effective, patient-centered treatments.
Keywords:
Biological Macromolecules, Diabetes management, Emerging TheparyDownloads
References
Institute for Health Metrics and Evaluation. Global diabetes cases to soar from 529 million to 1.3 billion by 2050 [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://www.healthdata.org/news - events/newsroom/news - releases/global - diabetes - cases - soar - 529 - million - 13 - billion - 2050.
Dilworth L, Facey A, Omoruyi F. Diabetes mellitus and its metabolic complications: The role of adipose tissues. Int J Mol Sci. 2021;22(14):7644. https://doi.org/10.3390/ijms22147644.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62 - 7. https://doi.org/10.2337/dc09 - S062.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753 - 86. https://doi.org/10.2337/dci22 - 0034.
Song H, Ma H, Shi J, Liu Y, Kan C, Hou N, et al. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules. Int J Biol Macromol. 2023;243:125148. https://doi.org/10.1016/j.ijbiomac.2023.125148.
Nayak AK, Dhara AK, Pal D. Biological macromolecules. In: Biological Macromolecules. Academic Press; 2022. p. 229 - 41. https://doi.org/10.1016/B978 - 0 - 323 - 85759 - 8.00010 - 5.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP - 1 receptor agonists in the treatment of type 2 diabetes – state - of - the - art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.
Ahrén B. Glucagon - like peptide - 1 receptor agonists for type 2 diabetes: A rational drug development. J Diabetes Investig. 2019;10(2):196 - 201. https://doi.org/10.1111/jdi.12911.
Lovshin JA, Drucker DJ. Incretin - based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(5):262 - 9. https://doi.org/10.1038/nrendo.2009.48.
Shahzad N, Alzahrani AR, Ibrahim IAA, Shahid I, Alanazi IM, Falemban AH, et al. Therapeutic strategy of biological macromolecules based natural bioactive compounds of diabetes mellitus and future perspectives: A systematic review. Heliyon. 2024;10(2):e24207. https://doi.org/10.1016/j.heliyon.2024.e24207.
Deacon CF, Holst JJ. Dipeptidyl peptidase - 4 inhibitors for the treatment of type 2 diabetes: Comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047 - 58. https://doi.org/10.1517/14656566.2013.824966.
Deacon CF. Dipeptidyl peptidase - 4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes Obes Metab. 2011;13(1):7 - 18. https://doi.org/10.1111/j.1463 - 1326.2010.01306.x.
Pan Y, Wang B, Zheng J, Xiong R, Fan Z, Ye Y, et al. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling - dependent manner. J Cell Mol Med. 2019;23(2):1059 - 71. https://doi.org/10.1111/jcmm.14007.
Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, et al. Involvement of growth factors in diabetes mellitus and its complications: A general review. Biomed Pharmacother. 2018;101:510 - 27. https://doi.org/10.1016/j.biopha.2018.02.105.
Biadgo B, Tamir W, Ambachew S. Insulin - like growth factor and its therapeutic potential for diabetes complications - mechanisms and metabolic links: A review. Rev Diabet Stud. 2020;16(1):24 - 34. https://doi.org/10.1900/RDS.2020.16.24.
Barnett AH. Lixisenatide: Evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011;6:67 - 79. https://doi.org/10.2147/CE.S15525.
Shuwa HA, Dallatu MK, Yeldu MH, Ahmed HM, Nasir IA. Effects of adalimumab, an anti - tumour necrosis factor - alpha (TNF - α ) antibody, on obese diabetic rats. Malays J Med Sci. 2018;25(4):51 - 62. https://doi.org/10.21315/mjms2018.25.4.5.
Chen S, Sbuh N, Veedu RN. Antisense oligonucleotides as potential therapeutics for type 2 diabetes. Nucleic Acid Ther. 2020;31(1):15 - 22. https://doi.org/10.1089/nat.2020.0891.
Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27 – 9955) on glucagon - stimulated glucose production in humans. Diabetologia. 2001;44(11):2018 - 24. https://doi.org/10.1007/s001250100006.
Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, et al. Long - term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha - cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331(3):871 - 81. https://doi.org/10.1124/jpet.109.157685.
Prasad KMR, Yang Z, Bleich D, Nadler JL. Adeno - associated virus vector mediated gene transfer to pancreatic beta cells. Gene Ther. 2000;7(18):1553 - 61. https://doi.org/10.1038/sj.gt.3301279.
Yang YW, Kotin RM. Glucose - responsive gene delivery in pancreatic islet cells via recombinant adeno - associated viral vectors. Pharm Res. 2000;17(9):1056 - 61. https://doi.org/10.1023/a:1026445426982.
Bozbulut R, Sanlier N. Promising effects of β - glucans on glycaemic control in diabetes. Trends Food Sci Technol. 2019;83:159 - 66. https://doi.org/10.1016/j.tifs.2018.11.018.
Singh RP, Bhardwaj A. β - glucans: A potential source for maintaining gut microbiota and the immune system. Front Nutr. 2023;10:1143682. https://doi.org/10.3389/fnut.2023.1143682.
Khatri R, Mazurek S, Petry SF, Linn T. Mesenchymal stem cells promote pancreatic β - cell regeneration through downregulation of FoxO1 pathway. Stem Cell Res Ther. 2020;11:497. https://doi.org/10.1186/s13287 - 020 - 02007 - 9.
Zang L, Hao H, Liu J, Li Y, Han W, Mu Y. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:36. https://doi.org/10.1186/s13098 - 017 - 0233 - 1.
de Klerk E, Hebrok M. Stem cell - based clinical trials for diabetes mellitus. Front Endocrinol. 2021;12:631463. https://doi.org/10.3389/fendo.2021.631463.
Wang CR, Tsai HW. Anti - and non - tumor necrosis factor - α - targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. World J Diabetes. 2021;12(3):238 - 60. https://doi.org/10.4239/wjd.v12.i3.238.
Rehman K, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance: How are they interlinked? J Biomed Sci. 2016;23:87. https://doi.org/10.1186/s12929 - 016 - 0303 - y.
Sen A, Mohanraj PS, Ranjan A, Rajendran V, ArulVijayaVani S, Balan Y, et al. Unraveling the role of tumor necrosis factor - alpha in diabetic peripheral neuropathy: A systematic review and meta - analysis. Cureus. 2023;15(12):e49926. https://doi.org/10.7759/cureus.49926.
Shende P, Patel C. siRNA: An alternative treatment for diabetes and associated conditions. J Drug Target. 2019;27(2):174 - 82. https://doi.org/10.1080/1061186X.2018.1476518.
Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;13(2):48 - 57.
Miyamoto J, Watanabe K, Taira S, Kasubuchi M, Li X, Irie J, et al. Barley β - glucan improves metabolic condition via short - chain fatty acids produced by gut microbial fermentation in high fat diet fed mice. PLoS One. 2018;13(4):e0196579. https://doi.org/10.1371/journal.pone.0196579.
Chen C, Huang X, Wang H, Geng F, Nie S. Effect of β - glucan on metabolic diseases: A review from the gut microbiota perspective. Curr Opin Food Sci. 2022;47:100907. https://doi.org/10.1016/j.cofs.2022.100907.
Song G, Pacini G, Ahrén B, D’Argenio DZ. Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. Peptides. 2017;88:74 - 9. https://doi.org/10.1016/j.peptides.2016.12.012.
Jiang W, Peng Y, Yang K. Cellular signaling pathways regulating β - cell proliferation as a promising therapeutic target in the treatment of diabetes. Exp Ther Med. 2018;16(4):3275 - 85. https://doi.org/10.3892/etm.2018.6603.
Hinnen D. Glucagon - like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202 - 10. https://doi.org/10.2337/ds16 - 0026.
Novikoff A, Müller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165:171003. https://doi.org/10.1016/j.peptides.2023.171003.
Templer S. Closed - loop insulin delivery systems: Past, present, and future directions. Front Endocrinol. 2022;13:919942. https://doi.org/10.3389/fendo.2022.919942.
Daly AB, Boughton CK, Nwokolo M, Hartnell S, Wilinska ME, Cezar A, et al. Fully automated closed - loop insulin delivery in adults with type 2 diabetes: An open - label, single - center, randomized crossover trial. Nat Med. 2023;29(1):203 - 8. https://doi.org/10.1038/s41591 - 022 - 02144 - z.
Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol. 2021;62:102426. https://doi.org/10.1016/j.jddst.2021.102426.
Lotfi M, Butler AE, Sukhorukov VN, Sahebkar A. Application of CRISPR - Cas9 technology in diabetes research. Diabet Med. 2024;41(1):e15240. https://doi.org/10.1111/dme.15240.
Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide - 1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521 - 39. https://doi.org/10.1007/s11154 - 021 - 09699 - 1.
Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: Clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657 -
https://doi.org/10.1007/s40262 - 015 - 0343 - 6.
Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75(10):1128 - 41. https://doi.org/10.1016/j.jacc.2019.12.063.
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al - Abdulrazzaq D, Vazquez EM, et al. Once - weekly exenatide in youth with type 2 diabetes. Diabetes Care. 2022;45(8):1833 - 40. https://doi.org/10.2337/dc21 - 2275.
Morieri ML, Frison V, Rigato M, D’Ambrosio M, Tadiotto F, Paccagnella A, et al. Effectiveness of dulaglutide in the real world and in special populations of type 2 diabetic patients. J Clin Endocrinol Metab. 2020;105(7):e2617 - 25. https://doi.org/10.1210/clinem/dgaa204.
Yoshikawa K, Tsuchiya A, Kido T, Ota T, Ikeda K, Iwakura M, et al. Long - term safety and efficacy of sitagliptin for type 2 diabetes mellitus in Japan: Results of a multicentre, open - label, observational post - marketing surveillance study. Adv Ther. 2020;37(5):2442 - 59. https://doi.org/10.1007/s12325 - 020 - 01293 - 2.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA. 2019;321(1):69 - 79. https://doi.org/10.1001/jama.2018.18269.
Gao RY, Hsu BG, Wu DA, Hou JS, Chen MC. Serum fibroblast growth factor 21 levels are positively associated with metabolic syndrome in patients with type 2 diabetes. Int J Endocrinol. 2019;2019:5163245. https://doi.org/10.1155/2019/5163245.
Araújo TG, Oliveira AG, Carvalho BM, Guadagnini D, Protzek AOP, et al. Hepatocyte growth factor plays a key role in insulin resistance - associated compensatory mechanisms. Endocrinology. 2012;153(12):5760 - 9. https://doi.org/10.1210/en.2012 - 1496.
Ballav C, Dhere A, Kennedy I, Agbaje OF, White S, Franklin R, et al. Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post - meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinol Diabetes Metab. 2020;3(3):e00130. https://doi.org/10.1002/edm2.130.
Shuwa HA, Dallatu MK, Yeldu MH, Ahmed HM, Nasir IA. Effects of adalimumab, an anti - tumour necrosis factor - alpha (TNF - α ) antibody, on obese diabetic rats. Malays J Med Sci. 2018;25(4):51 - 62. https://doi.org/10.21315/mjms2018.25.4.5.
Wen W, Wei Y, Gao S. Functional nucleic acids for the treatment of diabetic complications. Nanoscale Adv. 2023;5(20):5426 - 34. https://doi.org/10.1039/d3na00327b.
Zhang X, Wang J, Zhang T, Li S, Liu J, Li M, et al. Updated progress on polysaccharides with anti - diabetic effects through the regulation of gut microbiota: Sources, mechanisms, and structure – activity relationships. Pharmaceuticals. 2024;17(4):456. https://doi.org/10.3390/ph17040456.
Bani Hamad FR, Rahat N, Shankar K, Tsouklidis N. Efficacy of stem cell application in diabetes mellitus: Promising future therapy for diabetes and its complications. Cureus. 2021;13(2):e13563. https://doi.org/10.7759/cureus.13563.
Mukhopadhyay P, Sarkar K, Chakraborty M, Bhattacharya S, Mishra R, Kundu PP. Oral insulin delivery by self - assembled chitosan nanoparticles: In vitro and in vivo studies in diabetic animal model. Materials Science and Engineering: C. 2013;33(1):376 – 382. https://doi.org/10.1016/j.msec.2012.09.001.
Volpatti LR, Matranga MA, Cortinas AB, et al. Glucose - Responsive Nanoparticles for Rapid and Extended Self - Regulated Insulin Delivery. ACS Nano. 2020;14(1):488 - 497. doi:10.1021/acsnano.9b06395
Malathi, S., Nandhakumar, P., Pandiyan, V., Webster, T. J., & Balasubramanian, S. (2015). Novel PLGA - based nanoparticles for the oral delivery of insulin. International journal of nanomedicine, 10, 2207 – 2218. https://doi.org/10.2147/IJN.S67947
Wang, Y., Li, H., Rasool, A., Wang, H., Manzoor, R., & Zhang, G. (2024). Polymeric nanoparticles (PNPs) for oral delivery of insulin. Journal of nanobiotechnology, 22(1), 1. https://doi.org/10.1186/s12951 - 023 - 02253 - y
Joshi, H. M., Bhumkar, D. R., Joshi, K., Pokharkar, V., & Sastry, M. (2006). Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir, 22(1), 300 - 305. https://doi.org/10.1016/j.msec.2012.09.001
Choudhury, H., Pandey, M., Lim, Y. Q., Low, C. Y., Lee, C. T., Marilyn, T. C. L., ... & Gorain, B. (2020). Silver nanoparticles: Advanced and promising technology in diabetic wound therapy. Materials Science and Engineering: C, 112, 110925. https://doi.org/10.1016/j.msec.2020.110925
Marinheiro, Diogo et al. “Silica - Based Nanomaterials for Diabetes Mellitus Treatment.” Bioengineering (Basel, Switzerland) vol. 10,1 40. 29 Dec. 2022, doi:10.3390/bioengineering10010040
Shah, A., Aftab, S., Nisar, J., Ashiq, M. N., & Iftikhar, F. J. (2021). Nanocarriers for targeted drug delivery. Journal of Drug Delivery Science and Technology, 62, 102426. https://doi.org/10.1016/j.jddst.2021.102426
Anderson, J. M., & Shive, M. S. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced drug delivery reviews, 28(1), 5 - 24. https://doi.org/10.1016/S0169 - 409X(97)00048 - 3
Burdu ș el, A. C., Gherasim, O., Grumezescu, A. M., Mogoant ă , L., Ficai, A., & Andronescu, E. (2018). Biomedical Applications of Silver Nanoparticles: An Up - to - Date Overview. Nanomaterials (Basel, Switzerland), 8(9),
https://doi.org/10.3390/nano8090681
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle - based drug and gene delivery. Advanced drug delivery reviews, 99, 28 - 51. https://doi.org/10.1016/j.addr.2015.09.012
Tamborlane, W. V., Bishai, R., Geller, D., Shehadeh, N., Al - Abdulrazzaq, D., Vazquez, E. M., Karoly, E., Troja, T., Doehring, O., Carter, D., Monyak, J., & Sjöström, C. D. (2022). Once - Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes care, 45(8), 1833 – 1840. https://doi.org/10.2337/dc21 - 2275
Mukhopadhyay, P., Sarkar, K., Chakraborty, M., Bhattacharya, S., Mishra, R., & Kundu, P. P. (2013). Oral insulin delivery by self - assembled chitosan nanoparticles: in vitro and in vivo studies in diabetic animal model. Materials science & engineering. C, Materials for biological applications, 33(1), 376 – 382. https://doi.org/10.1016/j.msec.2012.09.001
Tatovic, D., McAteer, M. A., Barry, J., Barrientos, A., Rodríguez Terradillos, K., Perera, I., Kochba, E., Levin, Y., Dul, M., Coulman, S. A., Birchall, J. C., von Ruhland, C., Howell, A., Stenson, R., Alhadj Ali, M., Luzio, S. D., Dunseath, G., Cheung, W. Y., Holland, G., May, K., Ludvigsson, J. (2022). Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunotherapy advances, 2(1), ltac002. https://doi.org/10.1093/immadv/ltac002
Marinheiro, D., Martel, F., Ferreira, B. J. M. L., & Daniel - da - Silva, A. L. (2022). Silica - Based Nanomaterials for Diabetes Mellitus Treatment. Bioengineering (Basel, Switzerland), 10(1), 40. https://doi.org/10.3390/bioengineering10010040
Nayak, A. K., Hasnain, M. S., Behera, A., Dhara, A. K., & Pal, D. (2022). Biological macromolecules in drug delivery. In Biological Macromolecules (pp. 339 - 379). Academic Press. https://doi.org/10.1016/C2020 - 0 - 02562 - 4
Kafri M, Metzl - Raz E, Jona G, Barkai N. The cost of protein production. Cell Rep. 2016;14(1):22 - 31. https://doi.org/10.1016/j.celrep.2015.12.015.
Das SK, Mishra R, Samanta A, Shil D, Roy SD. Deep learning: A game changer in drug design and development. Adv Pharmacol. 2025;103:101 - 20. https://doi.org/10.1016/bs.apha.2025.01.008.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Dr. Sushanta Kumar Das; Dibyendu Shil, Amit Samanta, Subham Roy, Chayanika Goswami
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at